Veterinary Biomarkers Market Size, Share & Trends Analysis Report By Animal Type (Companion Animals, Production Animals), By Product (Biomarker, Kits & Reagents), By Application, By Disease Type, By Region, And Segment Forecasts, 2025 - 2030

Veterinary Biomarkers Market Size & Trends

The global veterinary biomarkers market size was estimated at USD 1.04 billion in 2024 and is expected to grow at a CAGR of 12.90% from 2025 to 2030. The increasing prevalence of chronic conditions such as cancer and cardiovascular diseases in animals is majorly increasing the demand for biomarker-based assay diagnostic kits in veterinary applications to predict disease in its early stages. The R&D activities implemented by key companies to enhance biomarker portfolios are fueling market growth.

In addition, the growing companion animal population and rising pet adoption rates are other factors boosting the market's growth. For instance, in October 2024, the American Veterinary Medical Association reported that the companion animal population had increased significantly from 1996 to 2024. Moreover, as per the APPA National Pet Owners Survey (2023-2024), 73.8 million households own a pet, which is over 66% of the total households. This is expected to contribute to market growth.

Some of the key drivers propelling the industry include the increasing adoption of R & D by key companies, expansion of product offerings, increased animal healthcare expenditure, and post-pandemic return to normal. For instance, according to the 2024 report published by the American Pet Products Association, the pet industry expenditure in the U.S. increased from USD 90.5 billion in 2018 to USD 150.6 billion in 2024. Similarly, as per the FEDIAF report published in June 2024, in 2022, nearly 29.2 billion will be spent on pet food products, and 24.6 billion will be spent on other pet-related services and products in Europe. These affirmative factors are attributed to the growth of the market during the forecast period.

Additionally, key players' strategic initiatives and increased R&D spending are accelerating veterinary biomarker market growth by driving innovation in diagnostic and therapeutic solutions. Companies invest in biomarker research to enhance early disease detection, improve treatment outcomes, and expand product portfolios. For instance, in January 2025, Virbac, in collaboration with Emmyon, Inc., introduced URSOLYX Soft Chews, incorporating ursolic acid to enhance canine muscle health. This innovation leverages skeletal muscle mRNA biomarkers to combat muscle atrophy, improving mobility in aging and active dogs. The launch highlights the growing role of biomarker-driven supplements in veterinary medicine, increasing the demand for precision health solutions in the pet care market.

Industry Concentration

The veterinary biomarkers market exhibits a medium level of industry concentration, with several key players contributing to its growth. Key players are actively engaged in research and development to enhance diagnostic precision and expand their product offerings, thereby driving market expansion.

Veterinary Biomarkers Industry Characteristics

The veterinary biomarkers market demonstrates a high degree of innovation, driven by advancements in molecular diagnostics, proteomics, and genomics. Key players like Zoetis, IDEXX Laboratories, and Thermo Fisher Scientific are investing in R&D to develop novel biomarkers for early disease detection and personalized veterinary medicine. Innovations include AI-driven diagnostic platforms and biomarker-based point-of-care testing, improving accuracy and efficiency in animal healthcare. This continuous innovation is expanding diagnostic capabilities and enhancing treatment outcomes in veterinary medicine.

The veterinary biomarkers market exhibits a strong level of collaborations and partnerships among key stakeholders, including biotech firms, research institutions, and veterinary healthcare providers. Companies like Zoetis, IDEXX, and Thermo Fisher Scientific frequently engage in strategic alliances, licensing agreements, and joint R&D projects to accelerate biomarker discovery and enhance diagnostic solutions. These collaborations drive innovation, expand product pipelines, and improve global access to advanced veterinary diagnostics.

Regulatory frameworks significantly impact the veterinary biomarkers market by ensuring product safety, efficacy, and quality. Agencies such as the FDA (CVM), EMA, and USDA impose strict guidelines on biomarker validation, diagnostic approvals, and commercialization. Compliance with evolving regulations can delay product launches but also enhance credibility and market adoption. Stringent policies drive innovation while increasing costs and time-to-market for new veterinary biomarker-based diagnostics.

The impact of product substitutes in the veterinary biomarkers market is moderate, as alternative diagnostic methods like traditional clinical assessments, imaging techniques (ultrasound, MRI), and molecular diagnostics can serve as substitutes. While these alternatives provide valuable insights, biomarkers offer higher specificity and early disease detection, making them preferable for precise diagnostics. However, cost constraints and accessibility of substitutes may influence market adoption in certain regions.

Increased R&D spending by key players is accelerating veterinary biomarker market growth by driving innovation in diagnostic and therapeutic solutions. Companies invest in biomarker research to enhance early disease detection, improve treatment outcomes, and expand product portfolios. For instance, in January 2025, Virbac, in collaboration with Emmyon, Inc., introduced URSOLYX Soft Chews, incorporating ursolic acid to enhance canine muscle health. This innovation leverages skeletal muscle mRNA biomarkers to combat muscle atrophy, improving mobility in aging and active dogs. The launch highlights the growing role of biomarker-driven supplements in veterinary medicine, increasing the demand for precision health solutions in the pet care market.

Animal Type Insights

The companion animals segment dominated the industry with the highest revenue share in 2024. This is due to the rising adoption rates of dogs and the significant disease prevalence rates among them. According to the American Kennel Club (AKC), In 2024, the U.S. dog population reached 89.7 million, with AKC registering over 1 million dogs. According to FEDIAF, Europe had an estimated 104 million dogs in 2023. In addition, the COVID-19 pandemic has encouraged most people worldwide to adopt dogs for psychological comfort.

The production animals segment is growing due to the increasing population of cattle and other livestock in developing countries such as China, India, and Japan. For instance, according to the United States Department of Agriculture (USDA), India's cattle population in 2024 is estimated at 307.42 million, a slight increase from 307.4 million in 2023. In addition, the growing prevalence of serious infectious diseases such as tuberculosis among the production animals is a major concern to increase numerous diagnostic approaches.

Product Type Insights

The biomarkers, kits & reagents segment held the largest market share in 2024. This is owing to the wide availability of major brands of biomarkers and test kits launched by key players in the market. Veterinarians prefer sensitive and accurate disease diagnostic approaches using biomarker test kits to understand the progression of the disorder and to provide specific treatments targeting the biological indicator of the disease. In addition, the growing awareness of biomarker application in the veterinary field in developing countries is fueling the growth of the market in recent years.

The biomarker readers segment is expected to grow over the forecast period owing to the growing diagnosis rate in veterinary practices. As human biomarker readers are not accurate and calibrated for animal readings, specific veterinary biomarker readers have been launched by the key players. For instance, Virbac launched an intuitive and compact laser-based fluorescent reader called Speed Reader that measures the biomarker concentration in animal serum or plasma samples exactly. This factor is fueling the growth of the segment in the market.

Application Insights

The disease diagnostics segment held the largest market share in 2024. This is owing to the growing number of veterinary admissions in both developed and developing countries for numerous disease diagnoses. In addition, the rising number of veterinary clinics and hospitals with trained veterinarians is another factor that boosts the growth of the segment. For instance, according to the Federation of Veterinarians of Europe, the number of veterinarians in Europe was approximately 328,494 in 2023.

The preclinical research segment is expected to grow over the forecast period owing to the increasing research and development activities in the area of veterinary biomarkers and post-genomic technologies. The advanced strategies initiated by animal health key players to identify novel biomarkers or disease indicators further enhance the opportunity for segment growth. For instance, in January 2024, Center Point Bio-Tech launched AlphaION, an advanced veterinary diagnostic system integrating AI, automation, and novel biomarker testing like surface acoustic wave (SAW) technology. AlphaION enhances point-of-care diagnostics, improving test sensitivity, antimicrobial stewardship, and workflow efficiency in veterinary practices.

Disease Type Insights

The inflammatory & infectious diseases segment held the largest market share of 39.34% in 2024. This is owing to the growing prevalence of various types of infectious diseases that arise among companion and production animals. The government's concern to prevent zoonotic disease transmission from animals to humans has led to multiple diagnostic strategies in many countries. The penetration of biomarker-based diagnostic kits is rising in such activities, thereby widening the scope of the products in the market.

Other disease types, such as cardiovascular diseases and cancer, are commonly prevailing among animals, demanding more attention for proper diagnosis. Most of these diseases are commonly asymptomatic and widely ignored until the progression of serious stages. For instance, according to the University of Kentucky UK, most of the cattle infected with cancer show no sign, thereby being neglected for timely treatments, leading to 5-20% of sudden death cases. Hence, the demand for accurate diagnostic tests to predict progressing diseases and their risk factors in benign stages is widely growing.

Regional Insights

North America veterinary biomarkers market held a 41.28% share in 2024. The high share of the region is due to the significant presence of key players, the adoption of various strategies initiated by key companies to increase market penetration, rising research activities, rising diagnostic rates, and increasing animal population & vet care expenditure. The growing number of veterinary clinics with licensed and trained veterinarians in the countries is another factor that boosts the growth of the market. According to the AVMA, in 2023, nearly 127,131 licensed veterinarians were estimated in the U.S., and they majorly catered to companion animal patients.

U.S. Veterinary Biomarkers Market Trends

The veterinary biomarkers market in the U.S. is experiencing significant growth, driven by the increasing prevalence of chronic conditions such as cancer and cardiovascular diseases in animals. This trend is fueling the demand for biomarker-based diagnostic assays that enable early disease detection. For instance, in June 2024, Oxford BioDynamics (OBD) developed EpiSwitch SCB, a highly accurate, non-invasive blood test for detecting six common canine cancers, including lymphoma, sarcoma, and melanoma. Validated through 3D whole-genome profiling, the test offers >89% accuracy for specific cancers, addressing a critical gap in veterinary oncology by providing precise cancer-type identification. EpiSwitch SCB is set for real-world validation and commercialization via partnerships, positioning OBD in the growing U.S. veterinary biomarkers market, where demand for advanced, non-invasive diagnostic solutions is increasing.

Europe Veterinary Biomarkers Market Trends

The veterinary biomarkers market in Europe is growing due to major key players such as Virbac, ACUVET BIOTECH, and others in European countries. The European market is driven by rising pet ownership, increasing prevalence of animal diseases, and advancements in diagnostic technologies. Growing demand for early disease detection, personalized treatments, and point-of-care testing boosts market growth. For example, in April 2024, VolitionRx, in partnership with Antech, launched the Nu.Q Vet Cancer Test for in-clinic use across Europe, enhancing rapid cancer screening in dogs. Operating on the Element i+ Analyzer, this biomarker-based test provides quick and cost-effective cancer detection, supporting early diagnosis and improved treatment outcomes in veterinary care.

The UK veterinary biomarkers market is set to witness lucrative growth due to advancements in diagnostic technologies, increasing pet ownership, and rising demand for early disease detection. Key trends include the adoption of AI-driven biomarker analysis, such as proteomics-based diagnostics for canine cancers and point-of-care testing for inflammatory diseases like feline pancreatitis. Regulatory support and investment in veterinary research further drive market expansion. Moreover, Market growth is anticipated to be supported by a number of measures taken by industry participants to increase diagnostic rates. For example, in November 2023, Veterinary Pathology Group (VPG) and VolitionRx introduced the Nu.Q Test in the UK and Ireland, offering veterinarians a non-invasive blood test for early canine cancer detection. This innovative biomarker-based screening enhances preventive care, improving diagnosis and treatment outcomes. Its introduction strengthens the UK veterinary biomarkers market by expanding diagnostic capabilities and advancing early disease detection.

The veterinary biomarkers market in Germany is growing due to increasing demand for early disease detection and precision diagnostics. German veterinary institutions and biotech firms are partnering to develop next-generation biomarkers for diseases like sepsis and inflammatory disorders in animals, enhancing the market’s growth. Similarly, innovations such as AI-driven biomarker analysis and multiplex assays are improving diagnostic accuracy and efficiency. Firms like Fraunhofer IZI are researching novel biomarker applications in veterinary medicine.

Asia Pacific Veterinary Biomarkers Market Trends

The veterinary biomarkers market in Asia Pacific is expanding quickly and is expected to grow faster over the forecast period. This is attributable to the rising animal healthcare expenditures and disposable income in key markets coupled with rising awareness for biomarkers in veterinary practices. The growing demand for the proper and timely diagnosis of numerous diseases and pet humanization in developing countries like India are further boosting the growth of the market.

India veterinary biomarkers market is estimated to exhibit a significant increase over the forecast period. This can be attributed to rising pet ownership, increased livestock health awareness, and advancements in veterinary diagnostics. The demand for early disease detection, particularly for conditions like cancer and infectious diseases, is driving the adoption of biomarker-based tests. Government initiatives and expanding veterinary healthcare infrastructure further support market expansion.

Latin America Veterinary Biomarkers Market Trends

The veterinary biomarkers market in Latin America is driven by increasing pet adoption, rising awareness of animal health, and advancements in veterinary diagnostics. Growing livestock production, particularly in Brazil and Argentina, fuels the demand for biomarkers to monitor disease outbreaks and improve productivity. Additionally, the expansion of veterinary diagnostic labs and point-of-care testing solutions enhances early disease detection and treatment.

Brazil veterinary biomarkers market is subject to a lucrative increase during the forecast period due to increasing livestock production, rising pet healthcare awareness, and advancements in diagnostic technologies. The country's strong cattle and poultry industries require biomarker-based disease detection to improve herd health and productivity. For example, biomarkers for mastitis in dairy cattle help reduce economic losses, while canine cancer diagnostics are gaining traction due to growing pet adoption and veterinary investments.

MEA Veterinary Biomarkers Market Trends

The veterinary biomarkers market in the Middle East & Africa is estimated to witness lucrative growth over the forecast period. The market is growing due to increasing livestock diseases, rising pet ownership, and advancements in veterinary diagnostics. Growing government initiatives to improve animal health, especially in countries like Saudi Arabia and South Africa, are boosting demand for biomarker-based disease detection. For example, biomarker testing for Foot-and-Mouth Disease in cattle helps prevent outbreaks, while rapid diagnostic tools for zoonotic diseases like Rift Valley Fever are gaining importance in the region.

South Africa veterinary biomarkers market is subject to lucrative growth in the coming years. The market is driven by rising demand for livestock disease management, increasing pet healthcare awareness, and advancements in veterinary diagnostics. The country's large cattle and poultry industries rely on biomarkers for early disease detection, such as bovine tuberculosis and avian influenza. Additionally, the growing pet care sector is fueling demand for biomarkers in companion animal cancer diagnostics and infectious disease monitoring. 

Key Veterinary Biomarkers Company Insights

The veterinary biomarkers market is emerging and consolidated. Leading players deploy numerous strategic initiatives, including competitive pricing strategies, partnerships, product expansion, sales & marketing initiatives, and mergers & acquisitions. For instance, in August 2024, FidoCure secured a groundbreaking patent for its AI-driven targeted therapy and biomarker for canine bladder cancer, revolutionizing cancer treatment in dogs. This novel approach, backed by real-world veterinary data, aims to enhance treatment efficacy while reducing side effects. With FDA approval in progress and eight more patents pending, FidoCure is advancing precision oncology in veterinary medicine.

Recent Developments

• In January 2025, Virbac, in collaboration with Emmyon, introduced URSOLYX Soft Chews, leveraging ursolic acid to enhance muscle biomarkers and improve functional performance in aging and active dogs.

• In September 2024, Boehringer Ingelheim International GmbH acquired Saiba Animal Health AG to strengthen its animal therapeutics portfolio. The company's innovative vaccine development platform is expected to enhance the veterinary oncology sector.

• In July 2024, Dechra Pharmaceuticals PLC acquired Invetx to bolster the company's existing pipeline. 

Veterinary Biomarkers Market Report Scope

Global Veterinary Biomarkers Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global veterinary biomarkers market report based on animal type, product type, application, disease type, and region:

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Companion Animals

    • Dogs

    • Cats

    • Others

  • Production Animals

    • Cows

    • Pigs

    • Others

• Product Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Biomarkers, Kits & Reagents

  • Biomarker Readers

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Disease Diagnostics

  • Preclinical Research

  • Others

• Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Inflammatory & Infectious Diseases

  • Cardiovascular Diseases

  • Skeletal Muscle Diseases

  • Tumor

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Sweden

    • Denmark

    • Norway

    • Rest of Europe

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Thailand

    • Rest of Asia Pacific

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of MEA